ALMS
HEALTHCAREAlumis Inc
AI Insight
What's Moving ALMS Today?
No stock-specific AI insight has been generated for ALMS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.92$30.60
$24.85
Fundamentals
Market Cap$3.1B
P/E Ratio—
EPS$-1.78
Dividend Yield—
Dividend / Share—
ROE-64.6%
Profit Margin—
Debt / Equity—
Trading
Volume956K
Avg Volume (10D)—
Shares Outstanding123.4M
ALMS News
25 articles- Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline AdvancementsYahoo Finance·May 29, 2026
- How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) InvestorsSimply Wall Street·May 25, 2026
- This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last QuarterMotley Fool·May 24, 2026
- Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40Moomoo·May 20, 2026
- Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?Yahoo Finance·May 20, 2026
- Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of SharesMotley Fool·May 19, 2026
- What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsMotley Fool·May 19, 2026
- [DEF 14A] ALUMIS INC. Definitive Proxy StatementStock Titan·May 19, 2026
- Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems BullishMotley Fool·May 18, 2026
- Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterThe Motley Fool·May 17, 2026
- Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting BackMotley Fool·May 15, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Oil Surge, Higher Yields, Geopolitical UncertaintyYahoo Finance·May 15, 2026
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersBiopharmadive·May 15, 2026
- A Look At Alumis (ALMS) Valuation After Revenue Drop And Narrowed Net LossYahoo Finance·May 15, 2026
- Alumis Reports First Quarter 2026 Financial Results and Highlights Recent AchievementsYahoo Finance·May 14, 2026
- C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 12, 2026
- Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune DrugMotley Fool·May 10, 2026
- Personalis (PSNL) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial ResultsYahoo Finance·Apr 6, 2026
- Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA PlansYahoo Finance·Apr 4, 2026
- Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For EnvudeucitinibYahoo Finance·Apr 4, 2026
- Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer SaysYahoo Finance·Mar 30, 2026
- Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus ReadoutMarketbeat·Mar 30, 2026
- Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque PsoriasisGlobeNewswire Inc.·Mar 28, 2026
All 25 articles loaded
Price Data
Open$24.35
Previous Close$24.51
Day High$25.06
Day Low$24.05
52 Week High$30.60
52 Week Low$2.92
52-Week Range
$2.92$30.60
$24.85
Fundamentals
Market Cap$3.1B
P/E Ratio—
EPS$-1.78
Dividend Yield—
Dividend / Share—
ROE-64.6%
Profit Margin—
Debt / Equity—
Trading
Volume956K
Avg Volume (10D)—
Shares Outstanding123.4M
About Alumis Inc
Alumis Inc. (ALMS) is a leader in the aluminum sector, dedicated to the innovation and commercialization of high-performance aluminum solutions tailored for critical industries such as automotive, aerospace, and construction. Leveraging proprietary technologies and a strong commitment to sustainable practices, Alumis advances materials science while prioritizing environmental stewardship. The company’s robust research and development efforts position it to capitalize on emerging market trends, offering a diversified product portfolio that meets evolving client demands. With a focus on operational excellence, Alumis is strategically equipped for sustained growth and long-term value creation for its investors.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—